Gold prices slide further as easing US-China tensions curb haven demand
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (NASDAQ:IRIX), a medical technology company with a market capitalization of $23.28 million, recently purchased a total of $1682 in company stock. According to a Form 4 filing with the Securities and Exchange Commission, the transactions, all of which occurred on September 11, 2025, involved the acquisition of Iridex common stock. The purchase comes as the stock has declined 18.45% year-to-date.
Dizon acquired a total of 1250 shares of Iridex in a series of transactions, with prices ranging from $1.34 to $1.35 per share. Following these transactions, Dizon directly owns 60,500 shares of Iridex. According to InvestingPro analysis, the stock appears slightly undervalued at its current price of $1.37, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US stocks.
In other recent news, Iridex Corporation reported its second-quarter earnings for 2025, surpassing expectations. The company achieved an earnings per share (EPS) of -$0.06, better than the forecasted -$0.09. Additionally, Iridex reported revenue of $13.6 million, exceeding the anticipated $13.1 million. These results highlight a positive performance for the company during this period. Furthermore, Iridex announced it has regained compliance with Nasdaq’s continued listing requirements. This follows a previous non-compliance notification received in May 2025, based on its quarterly report for the period ended March 29, 2025. The resolution of this listing issue marks a significant development for the company. These updates reflect recent developments concerning Iridex Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.